Literature DB >> 12239611

p27, cyclin E, and CDK2 expression in normal and cancerous endometrium.

T Oshita1, K Shigemasa, N Nagai, K Ohama.   

Abstract

The objective was to investigate the immunohistochemical expression of p27, cyclin E, and CDK2 in normal and cancerous endometrium. Expression of p27 in premenopausal normal endometrium was significantly higher than that in postmenopausal normal endometrium (p=0.019). A significantly lower amount of p27 staining was observed in endometrial cancer tissues from premenopausal women than in normal premenopausal endometrium (p=0.015). Cyclin E expression in premenopausal normal endometrium was significantly higher than that in postmenopausal normal endometrium (p=0.003). A significantly higher amount of cyclin E staining was observed in endometrial cancer tissues from postmenopausal women than in normal postmenopausal endometrium (p=0.017). Regarding menopausal status, no significant difference in CDK2 staining was observed between cancerous and normal endometrium. There was a positive significant correlation between cyclin E and CDK2 expression levels in endometrial cancers (p<0.05). Western blot analysis confirmed elevated p27 protein levels in samples with positive p27 immunostaining. Considerable levels of p27 mRNA were detected in all normal and cancerous samples examined by semi-quantitative PCR. No significant relationship was found between telomerase activity and its association with p27 and cyclin E expression in endometrial cancers. These findings suggested that the decreased expression of p27 caused by post-translational mechanism might play an important role in endometrial cancer development in premenopausal women. In addition, increased cyclin E expression may play an important role in endometrial cancer development in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239611     DOI: 10.3892/ijo.21.4.737

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.

Authors:  A S McCampbell; M L Mittelstadt; R Dere; S Kim; L Zhou; B Djordjevic; P T Soliman; Q Zhang; C Wei; S D Hursting; K H Lu; R R Broaddus; C L Walker
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

2.  Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome.

Authors:  A Villavicencio; A Goyeneche; C Telleria; K Bacallao; F Gabler; A Fuentes; M Vega
Journal:  Gynecol Oncol       Date:  2009-07-23       Impact factor: 5.482

3.  Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans.

Authors:  Hyun-Seuk Moon; John P Chamberland; Konstantinos Aronis; Sofia Tseleni-Balafouta; Christos S Mantzoros
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

4.  Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Authors:  Hui Yue; Hui-Yong Jiang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

5.  KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.

Authors:  Mei-Ting Qiu; Qiong Fan; Zhu Zhu; Suet-Ying Kwan; Limo Chen; Jin-Hong Chen; Zuo-Lin Ying; Ye Zhou; Wei Gu; Li-Hua Wang; Wei-Wei Cheng; Jianfang Zeng; Xiao-Ping Wan; Samuel C Mok; Kwong-Kwok Wong; Wei Bao
Journal:  Oncotarget       Date:  2015-10-13

6.  Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression).

Authors:  Sevgiye Kacar Ozkara; Aydin Corakci
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

7.  Study of the Association of Phosphatase and Tensin Homolog and p27 Expressions in Endometrial Hyperplasia and Carcinoma.

Authors:  Ihab Shafek Atta
Journal:  J Microsc Ultrastruct       Date:  2019 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.